KERX Financial Facts

Total operating expenses: 29M
Basic and diluted net loss per common share: -0.28
See Full Income Statement

Short-term investment securities: 0
Interest receivable: 0
See Full Balance Sheet

Keryx Biopharmaceuticals Inc. (KERX) Earnings

  |   Expand Research on KERX
Next EPS Date 8/5/15 EPS Growth Rate -8.3%
Average EPS % Beat Rate -12.2% Revenue Growth Rate N/A
Average % Move 1-Wk after EPS +1.2% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/6/14 Q314 -$0.38-$0.27 -$0.11$256K$150K N/A Details
11/4/13 Q313 -$0.19-$0.11 -$0.08N/A$2.22M N/A Details
5/8/14 Q114 -$0.15-$0.08 -$0.07$10M$9.91M N/A Details
2/27/15 Q414 -$0.44-$0.37 -$0.07$569K$1.39M N/A Details
3/12/14 Q413 -$0.21-$0.16 -$0.05N/A$2.22M N/A Details
7/31/13 Q213 -$0.14-$0.10 -$0.04N/AN/A N/A Details
3/8/11 Q410 -$0.09-$0.06 -$0.03N/A$2.82M N/A Details
11/2/11 Q311 -$0.15-$0.12 -$0.03N/AN/A N/A Details